^
Association details:
Evidence:
Evidence Level:
Sensitive: D – Preclinical
New
Source:
Title:

392 Engineering CD70-directed CAR-NK cells for the treatment of hematological and solid malignancies

Published date:
11/08/2022
Excerpt:
In functional assays, CD70 knockout CAR-NK cells mediated cytotoxicity against multiple CD70-positive tumor cell lines including AML and RCC both in vitro and in vivo….Overall, the results demonstrate the potential for targeting CD70 with CAR-NK cell therapy for the treatment of AML, RCC, and other CD70-positive malignancies...
DOI:
http://dx.doi.org/10.1136/jitc-2022-SITC2022.0392
Evidence Level:
Sensitive: D – Preclinical
Source:
Title:

1972 Investigation of ALLO-316: A Fratricide-Resistant Allogeneic CAR T Targeting CD70 As a Potential Therapy for the Treatment of AML

Published date:
11/04/2020
Excerpt:
ALLO-316 cells were highly effective at lysing CD70-expressing target cells and eliminated greater than 99% of cells at the high effector to target (E:T) ratio...Moreover, ALLO-316 cells were able to kill primary AML blasts with CD70 expression ex vivo.
DOI:
https://doi.org/10.1182/blood-2020-142161